Your browser doesn't support javascript.
loading
Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROC-DRT-Registry.
Sedaghat, Alexander; Vij, Vivian; Al-Kassou, Baravan; Gloekler, Steffen; Galea, Roberto; Fürholz, Monika; Meier, Bernhard; Valgimigli, Marco; O'Hara, Gilles; Arzamendi, Dabit; Agudelo, Victor; Asmarats, Lluis; Freixa, Xavier; Flores-Umanzor, Eduardo; De Backer, Ole; Søndergaard, Lars; Nombela-Franco, Luis; McInerney, Angela; Korsholm, Kaspar; Nielsen-Kudsk, Jens Erik; Afzal, Shazia; Zeus, Tobias; Operhalski, Felix; Schmidt, Boris; Montalescot, Gilles; Guedeney, Paul; Iriart, Xavier; Miton, Noelie; Saw, Jacqueline; Gilhofer, Thomas; Fauchier, Laurent; Veliqi, Egzon; Meincke, Felix; Petri, Nils; Nordbeck, Peter; Rycerz, Szymon; Ognerubov, Dmitrii; Merkulov, Evgeny; Cruz-González, Ignacio; Gonzalez-Ferreiro, Rocio; Bhatt, Deepak L; Laricchia, Alessandra; Mangieri, Antonio; Omran, Heyder; Schrickel, Jan Wilko; Rodes-Cabau, Josep; Nickenig, Georg.
Afiliação
  • Sedaghat A; University Hospital Bonn, Germany (A.S., V.V., B.A.-K., J.W.S., G.N.).
  • Vij V; University Hospital Bonn, Germany (A.S., V.V., B.A.-K., J.W.S., G.N.).
  • Al-Kassou B; University Hospital Bonn, Germany (A.S., V.V., B.A.-K., J.W.S., G.N.).
  • Gloekler S; University Hospital Bern, Switzerland (S.G., R.G., M.F., B.M., M.V.).
  • Galea R; University Hospital Bern, Switzerland (S.G., R.G., M.F., B.M., M.V.).
  • Fürholz M; University Hospital Bern, Switzerland (S.G., R.G., M.F., B.M., M.V.).
  • Meier B; University Hospital Bern, Switzerland (S.G., R.G., M.F., B.M., M.V.).
  • Valgimigli M; University Hospital Bern, Switzerland (S.G., R.G., M.F., B.M., M.V.).
  • O'Hara G; Cardiocentro Ticino, Lugano, Switzerland (M.V.).
  • Arzamendi D; Quebec Heart & Lung Institute, Laval University, Canada (G.O., L.A., J.R.-C.).
  • Agudelo V; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (D.A., V.A., L.A.).
  • Asmarats L; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (D.A., V.A., L.A.).
  • Freixa X; Quebec Heart & Lung Institute, Laval University, Canada (G.O., L.A., J.R.-C.).
  • Flores-Umanzor E; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (D.A., V.A., L.A.).
  • De Backer O; Hospital Clinic Barcelona, Spain (X.F., E.F.-U.).
  • Søndergaard L; Hospital Clinic Barcelona, Spain (X.F., E.F.-U.).
  • Nombela-Franco L; Rigshospitalet Copenhagen University Hospital, Denmark (O.D.B., L.S.).
  • McInerney A; Rigshospitalet Copenhagen University Hospital, Denmark (O.D.B., L.S.).
  • Korsholm K; Hospital Clinico San Carlos Madrid, Spain (L.N.-F., A. McInerney).
  • Nielsen-Kudsk JE; Hospital Clinico San Carlos Madrid, Spain (L.N.-F., A. McInerney).
  • Afzal S; University Hospital Aarhus, Denmark (K.K., J.E.N.-K.).
  • Zeus T; University Hospital Aarhus, Denmark (K.K., J.E.N.-K.).
  • Operhalski F; University Hospital Düsseldorf, Germany (S.A., T.Z.).
  • Schmidt B; University Hospital Düsseldorf, Germany (S.A., T.Z.).
  • Montalescot G; Agaplesion Bethanien Krankenhaus, CBB, Frankfurt, Germany (F.O., B.S.).
  • Guedeney P; Agaplesion Bethanien Krankenhaus, CBB, Frankfurt, Germany (F.O., B.S.).
  • Iriart X; Surbonne University Pitié-Salpêtrière Hospital (AP-HP) Paris, France (G.M., P.G.).
  • Miton N; Surbonne University Pitié-Salpêtrière Hospital (AP-HP) Paris, France (G.M., P.G.).
  • Saw J; University Hospital Bordeaux, France (X.I., N.M.).
  • Gilhofer T; University Hospital Bordeaux, France (X.I., N.M.).
  • Fauchier L; Vancouver General Hospital, Vancouver, Canada (J.S.).
  • Veliqi E; Stadtspital Waid and Triemli, Zürich, Switzerland (T.G.).
  • Meincke F; University Hospital Tours, France (L.F.).
  • Petri N; St. Georg Hospital Hamburg, Germany (E.V., F.M.).
  • Nordbeck P; St. Georg Hospital Hamburg, Germany (E.V., F.M.).
  • Rycerz S; University Hospital Würzburg, Germany (N.P., P.N.).
  • Ognerubov D; University Hospital Würzburg, Germany (N.P., P.N.).
  • Merkulov E; Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany (S.R.).
  • Cruz-González I; Russian Cardiology Research and Production Complex, Moscow (D.O., E.M.).
  • Gonzalez-Ferreiro R; Russian Cardiology Research and Production Complex, Moscow (D.O., E.M.).
  • Bhatt DL; University Hospital of Salamanca, CIBER CV, IBSAL, Spain (I.C.-G., R.G.-F.).
  • Laricchia A; University Hospital of Salamanca, CIBER CV, IBSAL, Spain (I.C.-G., R.G.-F.).
  • Mangieri A; Heart and Vascular Center, Brigham and Women's Hospital Harvard Medical School, Boston (D.L.B.).
  • Omran H; Maria Cecilia Hospital Cotignola, Italy (A.L., A. Mangieri).
  • Schrickel JW; Maria Cecilia Hospital Cotignola, Italy (A.L., A. Mangieri).
  • Rodes-Cabau J; Marienkrankenhaus, Bonn, Germany (H.O.).
  • Nickenig G; University Hospital Bonn, Germany (A.S., V.V., B.A.-K., J.W.S., G.N.).
Circ Cardiovasc Interv ; 14(5): e010195, 2021 05.
Article em En | MEDLINE | ID: mdl-34003661
BACKGROUND: Left atrial appendage closure is an established therapy in patients with atrial fibrillation. Although device-related thrombosis (DRT) is relatively rare, it is potentially linked to adverse events. As data on DRT characteristics, outcome, and treatment regimen are scarce, we aimed to assess these questions in a multicenter approach. METHODS: One hundred fifty-six patients with the diagnosis of DRT after left atrial appendage closure were included in the multinational EUROC-DRT registry. Baseline characteristics included clinical and echocardiographic data. After inclusion, all patients underwent further clinical and echocardiographic follow-up to assess DRT dynamics, treatment success, and outcome. RESULTS: DRT was detected after a median of 93 days (interquartile range, 54­161 days) with 17.9% being detected >6 months after left atrial appendage closure. Patients with DRT were at high ischemic and bleeding risk (CHA2DS2-VASc 4.5±1.7, HAS-BLED 3.3±1.2) and had nonparoxysmal atrial fibrillation (67.3%), previous stroke (53.8%), and spontaneous echo contrast (50.6%). The initial treatment regimens showed comparable resolution rates (antiplatelet monotherapy: 57.1%, dual antiplatelet therapy: 85.7%, vitamin K antagonists: 80.0%, novel oral anticoagulants: 75.0%, and heparin: 68.6%). After intensification or switch of treatment, complete DRT resolution was achieved in 79.5% of patients. Two-year follow-up revealed a high risk of mortality (20.0%) and ischemic stroke (13.8%) in patients with DRT. Patients with incomplete DRT resolution showed numerically higher stroke rates and increased mortality rates (stroke: 17.6% versus 12.3%, P=0.29; mortality: 31.3% versus 13.1%, P=0.05). CONCLUSIONS: A substantial proportion of DRT is detected >6 months after left atrial appendage closure, highlighting the need for imaging follow-up. Patients with DRT appear to be at a high risk for stroke and mortality. While DRT resolution was achieved in most patients, incomplete DRT resolution appeared to identify patients at even higher risk. Optimal DRT diagnostic criteria and treatment regimens are warranted.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Trombose / Apêndice Atrial / Acidente Vascular Cerebral Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Trombose / Apêndice Atrial / Acidente Vascular Cerebral Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article